Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 23

Sort by

Sort Order Select

Journal Articles

Inotuzumab Ozogamicin in Lymphoid B Cell Malignancy：a Single Center Analysis in the Real World

Mengnan Lv, Yi He, Donglin Yang, Qiaoling MA, Aiming Pang, Weihua Zhai, Jialin Wei, Xin Chen, Sizhou Feng, Mingzhe Han, Rongli Zhang, Erlie Jiang

Blood (2023) 142 (Supplement 1): 5900.

https://doi.org/10.1182/blood-2023-188534

Published: 2023

Journal Articles

Allogeneic Hematopoietic Stem Cell Transplantation for Classical Paroxysmal Nocturnal Hemoglobinuria

Xiaoli Zhao, Erlie Jiang, Xiaoyu Zhang, Shulian Chen, Lining Zhang, Mengze Hao, Yuanyuan SHI, Ming Gong, Jialin Wei, Yi He, Mingzhe Han

Blood (2023) 142 (Supplement 1): 6987.

https://doi.org/10.1182/blood-2023-181954

Published: 2023

Journal Articles

The Modified Melphalan-Cladribine-Busulfan-Cyclophosphamide (MCBC) Conditioning Regimen Improved Relapse-Free Survival after Allo-HSCT in Refractory/Relapsed AML

Xiaoyu Zhang, Shulian Chen, Weihua Zhai, Yi He, Sizhou Feng, Mingzhe Han, Ting Niu, Yajing Xu, Guangxun Gao, Shengjin Fan, Zepin Zhou, Fang Zhou, Rui Xi, Li Liu, Wei Yang, Xi Zhang, Qifa Liu, Erlie Jiang

Blood (2023) 142 (Supplement 1): 474.

https://doi.org/10.1182/blood-2023-184477

Published: 2023

Journal Articles

A Real-World Efficacy of Letermovir Primary Prophylaxis for Cytomegalovirus Infection after Allogeneic Hematopoietic Stem Cell Transplantation in China: A Single-Center Retrospective Analysis

Xiaoyu Zhang, Donglin Yang, Aiming Pang, Yi He, Jialin Wei, Rongli Zhang, Weihua Zhai, Qiaoling MA, Xin Chen, Mingzhe Han, Sizhou Feng, Erlie Jiang

Blood (2023) 142 (Supplement 1): 7027.

https://doi.org/10.1182/blood-2023-182816

Published: 2023

Journal Articles

A Modified Busulfan/Cyclophosphamide Preconditioning Regimen Incorporating Selinexor for Allogeneic Hematopoietic Stem Cell Transplantation in Relapsed/Refractory Hematologic Malignancies

Xiaofei Ni, Weihua Zhai, AiMing Pang, Donglin Yang, Xin Chen, Qiaoling MA, Jialin Wei, Yi He, Sizhou Feng, Mingzhe Han, Rongli Zhang, Erlie Jiang

Blood (2023) 142 (Supplement 1): 6974.

https://doi.org/10.1182/blood-2023-181449

Published: 2023

Journal Articles

Venetoclax Plus Azacitidine Versus Azacitidine Alone As Post-Transplant Maintenance Treatment in High-Risk AML and MDS

Yigeng Cao, Wenwen Guo, Weihua Zhai, Jialin Wei, Qiaoling MA, Donglin Yang, AiMing Pang, Mingzhe Han, Erlie Jiang

Blood (2023) 142 (Supplement 1): 4952.

https://doi.org/10.1182/blood-2023-180847

Published: 2023

Journal Articles

Analysis of Post-Transplant Clinical Outcomes and Prognostic Factors in FLT3-ITD Mutated Acute Myeloid Leukemia Patients Under ELN 2022 Risk Stratification

Chen Liang, Aiming Pang, Yi He, Donglin Yang, Rongli Zhang, Qiaoling MA, Mingzhe Han, Sizhou Feng, Erlie Jiang

Blood (2023) 142 (Supplement 1): 3619.

https://doi.org/10.1182/blood-2023-184582

Published: 2023

Journal Articles

The Efficacy and Safety of the Third Generation TKI Olverembatinib in Adult Ph+ Acute Lymphoblastic Leukemia with Relapsed Disease or Persistent MRD Bridging to Allo-HSCT: A Case Series from a Single Center

Xiaoyu Zhang, Yanhong Zhao, Rongli Zhang, Weihua Zhai, Yi He, Jialin Wei, Donglin Yang, Aiming Pang, Qiaoling MA, Xin Chen, Mingzhe Han, Sizhou Feng, Erlie Jiang

Blood (2023) 142 (Supplement 1): 5892.

https://doi.org/10.1182/blood-2023-184400

Published: 2023

Journal Articles

Efficacy and Safety of Olverembatinib-Based Therapies in Patients with Ph/BCR-ABL1-Positive Acute Lymphoblastic Leukemia

Yanhong Zhao, Weihua Zhai, Aiming Pang, Donglin Yang, Yi He, Jialin Wei, Qiaoling MA, Xin Chen, Mingzhe Han, Sizhou Feng, Rongli Zhang, Erlie Jiang

Blood (2023) 142 (Supplement 1): 5893.

https://doi.org/10.1182/blood-2023-184565

Published: 2023

Journal Articles

The Efficacy of Modified Melphalan and Busulfan-Based Conditioning Regimen for Autologous-HSCT in Low-Risk and Intermediate-Risk AML Patients

Weihua Zhai, Shulian Chen, Xiaoyu Zhang, Yi He, Sizhou Feng, Mingzhe Han, Xingli Zhao, Jie Bai, Lijuan Li, Zhihua Zhang, Ying Wang, Erlie Jiang, Jianxiang Wang

Blood (2023) 142 (Supplement 1): 7073.

https://doi.org/10.1182/blood-2023-180077

Published: 2023

Journal Articles

Comparison of Hematopoietic Stem Cell Transplantation and Repeated Immunosuppressive Therapy As Second-Line Treatment for Relapsed/Refractory Severe Aplastic Anemia

Lining Zhang, Jianping Li, Weiru Liang, Jialin Wei, Yi He, Erlie Jiang, Fengkui Zhang, Mingzhe Han, Sizhou Feng

Blood (2023) 142 (Supplement 1): 7095.

https://doi.org/10.1182/blood-2023-179202

Published: 2023

Journal Articles

The Efficacy and Safety of Modified Melphalan and Busulfan-Based Conditioning Regimen for Allogeneic-HSCT in Refractory/Relapsed or Persistent MRD Positive AML Patients

Shulian Chen, Xiaoyu Zhang, Weihua Zhai, Yi He, Sizhou Feng, Mingzhe Han, Ting Niu, Yajing Xu, Guangxun Gao, Shengjin Fan, Zeping Zhou, Fang Zhou, Xi Rui, Li Liu, Wei Yang, Qifa Liu, Xi Zhang, Erlie Jiang

Blood (2022) 140 (Supplement 1): 10467–10468.

https://doi.org/10.1182/blood-2022-165140

Published: 2022

Journal Articles

Comparison of Hematopoietic Stem Cell Transplantation and Immunosuppressive Therapy for Patients with Severe Hepatitis-Associated Aplastic Anemia

Xiaoyu Zhang, Wenrui Yang, Jialin Wei, Rongli Zhang, Guixin Zhang, Xin Chen, Yong Huang, Yingchang Mi, Sizhou Feng, Mingzhe Han, Li Zhang, Yi He, Erlie Jiang

Blood (2022) 140 (Supplement 1): 12941–12942.

https://doi.org/10.1182/blood-2022-165138

Published: 2022

Journal Articles

Effect of Two Conditionings on Relapse in Myelodysplastic Syndrome and Secondary Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation

Blood (2022) 140 (Supplement 1): 2392.

https://doi.org/10.1182/blood-2022-158688

Published: 2022

Journal Articles

Combination of Cytogenetic Classification and MRD Status Correlates with Outcomes of Autologous Versus Allogeneic Stem Cell Transplantation in Adults with B Cell-Acute Lymphoblastic Leukemia in First Remission

Rongli Zhang, Mengnan Lyu, Yi He, Donglin Yang, Aiming Pang, Jialin Wei, Qiaoling Ma, Weihua Zhai, Xin Chen, Guixin Zhang, Sizhou Feng, Mingzhe Han, Erlie Jiang

Blood (2022) 140 (Supplement 1): 7714–7715.

https://doi.org/10.1182/blood-2022-165085

Published: 2022

Journal Articles

Long-Term Efficacy Analysis of Allogeneic Hematopoietic Stem Cell Transplantation in the Treatment of Acute Myeloid Leukemia Using Melphalan Instead of Cyclophosphamide As a Myeloablative Conditioning Regimen

Ying Zhang, Aiming Pang, Donglin Yang, Yong Huang, Jialin Wei, Yi He, Qiaoling Ma, Sizhou Feng, Mingzhe Han, Erlie Jiang

Blood (2022) 140 (Supplement 1): 12842–12843.

https://doi.org/10.1182/blood-2022-167070

Published: 2022

Journal Articles

Which Patients with Ph+ Acute Lymphoblastic Leukemia Should Undergo Autologous Hematopoietic Stem Cell Transplantation in TKI Era?

Xin Liu, MD PhD, Erlie Jiang, Yong Huang, Lugui Qiu, MD, Sizhou Feng, Mingzhe Han, MD

Blood (2017) 130 (Supplement 1): 3286.

https://doi.org/10.1182/blood.V130.Suppl_1.3286.3286

Published: 2017

Journal Articles

Clinical Significance of Myeloblasts Percentage in the De Novo Acute Myeloid Leukemia with Erythroid Hyperplasia

Shaowei Qiu, MD, Hui Wei, MD PhD, Dong Lin, MD PhD, Guangji Zhang, Shuning Wei, Chunlin Zhou, MD PhD, Kaiqi Liu, Ying Wang, MD, Bingcheng Liu, Yuntao Liu, Benfa Gong, Xiaoyuan Gong, MD, Sizhou Feng, Yingchang Mi, MD PhD, Mingzhe Han, Jianxiang Wang, MD

Blood (2016) 128 (22): 5245.

https://doi.org/10.1182/blood.V128.22.5245.5245

Published: 2016

Journal Articles

Successful Treatment of Animal Models of Acute Graft-Versus-Host Disease with Small-Molecule TNF Inhibitor

Haiyan Gong, Yigeng Cao, Peng Liu, Haiyan Zhu, Zhezhe Wang, Fei Xiang, Tong Wang, Sizhou Feng, Mingzhe Han, Hongbo R. Luo, Jiaxi Zhou, Yuanfu Xu

Blood (2016) 128 (22): 4714.

https://doi.org/10.1182/blood.V128.22.4714.4714

Published: 2016

Journal Articles

Treatment Outcome and Prognostic Model for Stage IE/IIE Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type: A Retrospective Study in a Cohort of 305 Patients with Long Term Follow-up

Yuankai Shi, MD PhD, Bo Jia, Xiaohui He, MD, Youwu Shi, Mei Dong, MD, Jianliang Yang, MD, Liqiang Zhou, MD, Shengyu Zhou, MD, Peng Liu, MD, Yan Qin, MD, Sheng Yang, MD, Hua Lin, MD, Lin Gui, MD, Changgong Zhang, MD, Lin Wang, MD, Shanshan Chen, MD, Puyuan Xing, MD, Hongnan Mo, MD, Mingzhe Han, MD

Blood (2015) 126 (23): 2718.

https://doi.org/10.1182/blood.V126.23.2718.2718

Published: 2015

NARROW

Inotuzumab Ozogamicin in Lymphoid B Cell Malignancy：a Single Center Analysis in the Real World

Allogeneic Hematopoietic Stem Cell Transplantation for Classical Paroxysmal Nocturnal Hemoglobinuria

The Modified Melphalan-Cladribine-Busulfan-Cyclophosphamide (MCBC) Conditioning Regimen Improved Relapse-Free Survival after Allo-HSCT in Refractory/Relapsed AML

A Real-World Efficacy of Letermovir Primary Prophylaxis for Cytomegalovirus Infection after Allogeneic Hematopoietic Stem Cell Transplantation in China: A Single-Center Retrospective Analysis

A Modified Busulfan/Cyclophosphamide Preconditioning Regimen Incorporating Selinexor for Allogeneic Hematopoietic Stem Cell Transplantation in Relapsed/Refractory Hematologic Malignancies

Venetoclax Plus Azacitidine Versus Azacitidine Alone As Post-Transplant Maintenance Treatment in High-Risk AML and MDS

Analysis of Post-Transplant Clinical Outcomes and Prognostic Factors in FLT3-ITD Mutated Acute Myeloid Leukemia Patients Under ELN 2022 Risk Stratification

The Efficacy and Safety of the Third Generation TKI Olverembatinib in Adult Ph+ Acute Lymphoblastic Leukemia with Relapsed Disease or Persistent MRD Bridging to Allo-HSCT: A Case Series from a Single Center

Efficacy and Safety of Olverembatinib-Based Therapies in Patients with Ph/BCR-ABL1-Positive Acute Lymphoblastic Leukemia

The Efficacy of Modified Melphalan and Busulfan-Based Conditioning Regimen for Autologous-HSCT in Low-Risk and Intermediate-Risk AML Patients

Comparison of Hematopoietic Stem Cell Transplantation and Repeated Immunosuppressive Therapy As Second-Line Treatment for Relapsed/Refractory Severe Aplastic Anemia

The Efficacy and Safety of Modified Melphalan and Busulfan-Based Conditioning Regimen for Allogeneic-HSCT in Refractory/Relapsed or Persistent MRD Positive AML Patients

Comparison of Hematopoietic Stem Cell Transplantation and Immunosuppressive Therapy for Patients with Severe Hepatitis-Associated Aplastic Anemia

Effect of Two Conditionings on Relapse in Myelodysplastic Syndrome and Secondary Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation

Combination of Cytogenetic Classification and MRD Status Correlates with Outcomes of Autologous Versus Allogeneic Stem Cell Transplantation in Adults with B Cell-Acute Lymphoblastic Leukemia in First Remission

Long-Term Efficacy Analysis of Allogeneic Hematopoietic Stem Cell Transplantation in the Treatment of Acute Myeloid Leukemia Using Melphalan Instead of Cyclophosphamide As a Myeloablative Conditioning Regimen

Which Patients with Ph+ Acute Lymphoblastic Leukemia Should Undergo Autologous Hematopoietic Stem Cell Transplantation in TKI Era?

Clinical Significance of Myeloblasts Percentage in the De Novo Acute Myeloid Leukemia with Erythroid Hyperplasia

Successful Treatment of Animal Models of Acute Graft-Versus-Host Disease with Small-Molecule TNF Inhibitor

Treatment Outcome and Prognostic Model for Stage IE/IIE Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type: A Retrospective Study in a Cohort of 305 Patients with Long Term Follow-up

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only